• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

High cost of MS in Canada

May 16, 2012  

IFN-beta in CIS: phase III REFLEX results

May 2, 2012  

Oral anti-alpha4-integrin in development

March 14, 2012  

Alemtuzumab: high rate of autoimmune disorders

December 14, 2011  

Emerging MS therapies: update on injectable drugs

November 30, 2011  

CONFIRM – Second phase III trial results for BG-12

November 30, 2011  

No benefit with simvastatin add-on therapy in MS

November 9, 2011  

Laquinimod: Few cheers for BRAVO results

September 21, 2011  

Beta-IFN injections in the morning may improve flu-like symptoms

September 7, 2011  

No gain with higher dose of glatiramer acetate

August 24, 2011  
Previous
36
37
38
39
40
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions